Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21713889 | 0.90 | DPP4 (0.42) | DPP4DPP8DPP9DPP7SLC22A12 | |
| SCHEMBL21714418 | 0.88 | SLC22A12 (0.41) | DPP4DPP8DPP9DPP7SLC22A12 | |
| SCHEMBL21713306 | 0.88 | HPGD (0.39) | DPP4DPP8DPP9DPP7SLC22A12 | |
| SCHEMBL21714007 | 0.87 | SLC22A12 (0.40) | DPP4DPP8DPP9DPP7SLC22A12 | |
| SCHEMBL29819270 | 0.87 | APP (0.46) | DPP4SLC22A12 | |
| SCHEMBL21713966 | 0.87 | APP (0.46) | DPP4SLC22A12 | |
| SCHEMBL21713983 | 0.86 | DPP4 (0.44) | DPP4DPP8DPP9DPP7SLC22A12 | |
| SCHEMBL21713410 | 0.86 | DPP4 (0.44) | DPP4DPP8DPP9DPP7SLC22A12 | |
| SCHEMBL21714141 | 0.81 | HPGD (0.45) | DPP4DPP8DPP9DPP7SLC22A12 | |
| SCHEMBL21714012 | 0.78 | DPP4 (0.45) | DPP4DPP8DPP9DPP7SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4364804-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica NV (BE) | 2024-05-08 | — | — | EP | disclosed |
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| EP-3833662-B1 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| EP-3833662-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica N.V. (BE) | 2021-06-16 | — | — | EP | disclosed |
| US-10947252-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-16 | — | — | US | disclosed |
| WO-2020041169-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-27 | — | — | WO | disclosed |
| US-20200055874-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | DPP4 4374/4885DPP8 4295/4885DPP9 4191/4885 |
| US-20200055874-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | DPP4 4374/4885DPP8 4295/4885DPP9 4191/4885 |
| US-10947252-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | DPP4 4374/4885DPP8 4295/4885DPP9 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.